Dr. Shiela McCollam, PharmD, BCPS, Dr. Colleen Shipman, PharmD, MPH, BCPS, Dr. Joseph Bubalo, PharmD, BCPS, BCOP, Dr. Sacha Krieg, MD, PHD, FACOG
Many chemotherapy agents have the potential to impair fertility.1,2 Infertility resulting from cancer treatments can affect the quality of life for young cancer survivors.3 In 2017, an estimated 852,630 female patients were diagnosed with cancer in the United States, of whom 10.5% were aged <45 years.4
A paradigm shift in the management of relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) and low-grade non-Hodgkin lymphoma (NHL) has evolved in recent years. With increased use of targeted therapies, ibrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, is an integral therapeutic option for patients with treatment-naïve and treatment-experienced CLL or low-grade NHL. Ibrutinib therapy demonstrated superior overall response rates compared with ofatumumab and other agents in treatment-experienced patients with CLL.
Linda Blake, PharmD, PhD, BCPS, Alison Palumbo, PharmD, MPH, BCOP, Amber Diaz, PharmD, BCOP, Dr. Joseph Bubalo, PharmD, BCPS, BCOP
Targeting and inhibiting the vascular endothelial growth factor (VEGF)-signaling pathway has become an integral modality in the treatment of a variety of malignancies, including renal-cell carcinoma (RCC); glioblastoma; hepatocellular carcinoma; gastrointestinal stromal tumors; and colorectal, lung, gastric, and ovarian cancers.
Results 1 - 7 of 7